Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study - Summary - MDSpire

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study

  • By

  • Chang, Xiaoli

  • He, Zhangyuting

  • Wang, Huanyuan

  • Zhu, Huiying

  • Guo, Yixian

  • Zou, Dongmei

  • Zhao, Zhilian

  • Song, Tianbin

  • Hu, Ronghua

  • Ni, Jing

  • Zhao, Hong

  • Hui, Wuhan

  • Liu, Zixian

  • Li, Zhenling

  • Zhang, Wei

  • Zhou, Daobin

  • Zhang, Yan

  • Sun, Wanling

  • March 2, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of BTK inhibitors versus lenalidomide as maintenance therapy in newly diagnosed primary CNS lymphoma (PCNSL) patients, focusing on overall survival and progression-free survival.

Key Findings:
  • Both BTK inhibitors and lenalidomide showed potential in prolonging remission in newly diagnosed PCNSL, with specific response rates.
  • The study highlighted the importance of maintenance therapy in preventing relapse and extending overall survival, with implications for clinical practice.
  • Patient selection and treatment adherence were influenced by individual responses and socioeconomic factors, which should be considered in future studies.
Interpretation:

The findings suggest that both BTK inhibitors and lenalidomide are viable options for maintenance therapy in PCNSL, potentially improving patient outcomes, warranting further investigation into their long-term effects.

Limitations:
  • Retrospective design may introduce selection bias, and potential confounding factors should be acknowledged.
  • Limited sample size and variability in treatment regimens across centers may affect the generalizability of the results.
Conclusion:

BTK inhibitors and lenalidomide represent promising maintenance therapies for newly diagnosed PCNSL, warranting further prospective studies to validate these findings and explore their long-term efficacy.

Original Source(s)

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study

  • by Chang, Xiaoli, He, Zhangyuting, Wang, Huanyuan, Zhu, Huiying, Guo, Yixian, Zou, Dongmei, Zhao, Zhilian, Song, Tianbin, Hu, Ronghua, Ni, Jing, Zhao, Hong, Hui, Wuhan, Liu, Zixian, Li, Zhenling, Zhang, Wei, Zhou, Daobin, Zhang, Yan, Sun, Wanling

  • March 2, 2026

Related Content

Clinical GBM hybrid artificial intelligence for prescription dose recommendation and outcome prediction after gamma knife radiosurgery treatment: a proof-of-concept

Dana Farber/Boston Children’s Researchers Uncover Distinct Tumor “neighborhoods” with Each Cell Subtype Playing a Specific Role, in Aggressive Childhood Brain Cancer

Their detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas 

  • by

  • March 12, 2026

  • 3 min
Brain metastases from colorectal cancer – a retrospective dual center study